On November 16, 2026, FDA issued a proposed rule that would permit N-acetyl-L-cysteine (NAC) to be lawfully marketed in or as a dietary supplement, provided the product otherwise complies with requirements applicable to dietary supplements. The proposal is FDA’s first use of its statutory authority to permit an ingredient approved as a drug to be lawfully marketed in dietary supplements, and its first detailed explanation of the showing FDA believes is necessary to obtain such an exception. If finalized, the rule would establish a regulation entitled “dietary ingredients not excluded from the dietary supplement definition,” with NAC as the first entry and a placeholder for future additions.
Click here to read the full alert on cov.com.